Historical Valuation
Repare Therapeutics Inc (RPTX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 11.08 is considered Overvalued compared with the five-year average of -5.24. The fair price of Repare Therapeutics Inc (RPTX) is between 1.35 to 2.35 according to relative valuation methord. Compared to the current price of 2.54 USD , Repare Therapeutics Inc is Overvalued By 8.08%.
Relative Value
Fair Zone
1.35-2.35
Current Price：2.54
8.08%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Repare Therapeutics Inc (RPTX) has a current Price-to-Book (P/B) ratio of 0.96. Compared to its 3-year average P/B ratio of 0.96 , the current P/B ratio is approximately -0.55% higher. Relative to its 5-year average P/B ratio of 1.90, the current P/B ratio is about -49.44% higher. Repare Therapeutics Inc (RPTX) has a Forward Free Cash Flow (FCF) yield of approximately -63.32%. Compared to its 3-year average FCF yield of -70.52%, the current FCF yield is approximately -10.22% lower. Relative to its 5-year average FCF yield of -45.50% , the current FCF yield is about 39.15% lower.
P/B
Median3y
0.96
Median5y
1.90
FCF Yield
Median3y
-70.52
Median5y
-45.50
Competitors Valuation Multiple
AI Analysis for RPTX
The average P/S ratio for RPTX competitors is 10.31, providing a benchmark for relative valuation. Repare Therapeutics Inc Corp (RPTX.O) exhibits a P/S ratio of 11.08, which is 7.41% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for RPTX
1Y
3Y
5Y
Market capitalization of RPTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of RPTX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is RPTX currently overvalued or undervalued?
Repare Therapeutics Inc (RPTX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 11.08 is considered Overvalued compared with the five-year average of -5.24. The fair price of Repare Therapeutics Inc (RPTX) is between 1.35 to 2.35 according to relative valuation methord. Compared to the current price of 2.54 USD , Repare Therapeutics Inc is Overvalued By 8.08% .
What is Repare Therapeutics Inc (RPTX) fair value?
RPTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Repare Therapeutics Inc (RPTX) is between 1.35 to 2.35 according to relative valuation methord.
How does RPTX's valuation metrics compare to the industry average?
The average P/S ratio for RPTX's competitors is 10.31, providing a benchmark for relative valuation. Repare Therapeutics Inc Corp (RPTX) exhibits a P/S ratio of 11.08, which is 7.41% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Repare Therapeutics Inc (RPTX) as of Jan 10 2026?
As of Jan 10 2026, Repare Therapeutics Inc (RPTX) has a P/B ratio of 0.96. This indicates that the market values RPTX at 0.96 times its book value.
What is the current FCF Yield for Repare Therapeutics Inc (RPTX) as of Jan 10 2026?
As of Jan 10 2026, Repare Therapeutics Inc (RPTX) has a FCF Yield of -63.32%. This means that for every dollar of Repare Therapeutics Inc’s market capitalization, the company generates -63.32 cents in free cash flow.
What is the current Forward P/E ratio for Repare Therapeutics Inc (RPTX) as of Jan 10 2026?
As of Jan 10 2026, Repare Therapeutics Inc (RPTX) has a Forward P/E ratio of -2.69. This means the market is willing to pay $-2.69 for every dollar of Repare Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Repare Therapeutics Inc (RPTX) as of Jan 10 2026?
As of Jan 10 2026, Repare Therapeutics Inc (RPTX) has a Forward P/S ratio of 11.08. This means the market is valuing RPTX at $11.08 for every dollar of expected revenue over the next 12 months.